Serum antibodies to conformational and linear epitopes of myelin oligodendrocyte glycoprotein are not elevated in the preclinical phase of multiple sclerosis

Abstract

Background: The proposed predictive value of serum anti-myelin antibodies for the development of multiple sclerosis after a first clinically isolated syndrome was recently challenged.

Objective: To investigate myelin autoantibodies before first disease manifestation using different detection methods.

Methods: Patients with multiple sclerosis who had donated blood at a time prior to development of clinically isolated syndrome were identified via the German National Multiple Sclerosis Society. Control sera were obtained from age- and gender-matched blood donors. IgG-/IgM-antibodies against the extracellular part of native, cell surface-expressed myelin oligodendrocyte glycoprotein were detected by flow cytometry. Antibodies against linear epitopes were identified by immunoblot using recombinant myelin oligodendrocyte glycoprotein (aa1-125) and human myelin basic protein preparations.

Results: Fifty eight serum samples from 25 patients covering an interval of 7.3 years—2 months prior to disease onset were available. Longitudinal investigations were performed in 19 patients (2—14 samples per patient, 7 years—2 months prior to disease onset). No significant differences in the prevalence or titres of anti-myelin antibodies were detected between sera of preclinical individuals and healthy donors by either flow cytometry or immunoblot. There was no correlation between interval before clinically isolated syndrome and autoantibody status. Occurrence of antibodies was not associated with symptomatology/severity of clinically isolated syndrome.

Conclusion: Neither anti-myelin autoantibodies against cell surface-expressed native myelin oligodendrocyte glycoprotein nor against linear epitopes have a predictive or discriminative role during the preclinical disease phase for developing clinically isolated syndrome or multiple sclerosis later in life.

Keywords

Autoantibodies autoimmune diseases clinically isolated syndrome myelin antibodies surrogate marker

Get full access to this article

View all access options for this article.

References

Berger T. , Rubner P. , Schautzer F. , Egg R. , Ulmer H. , Mayringer I. , et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 2003; 349: 139-145.

Kuhle J. , Pohl C. , Mehling M. , Edan G. , Freedman MS , Hartung HP , et al. Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med 2007; 356: 371-378.

Pelayo R. , Tintore M. , Montalban X. , Rovira A. , Espejo C. , Reindl M. , et al. Antimyelin antibodies with no progression to multiple sclerosis . N Engl J Med 2007; 356: 426-428.

Zhou D. , Srivastava R. , Nessler S. , Grummel V. , Sommer N. , Brück W. , et al. Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proc Natl Acad Sci U S A 2006; 103: 19057-19062.

Lalive PH , Menge T. , Delarasse C. , Della GB , Pham-Dinh D. , Villoslada P. , et al. Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis. Proc Natl Acad Sci U S A 2006; 103: 2280-2285.

O’Connor KC , McLaughlin KA , De Jager PL , Chitnis T. , Bettelli E. , Xu C. , et al. Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med 2007; 13: 211-217.

Brilot F. , Dale RC , Selter RC , Grummel V. , Kalluri SR , Aslam M. , et al. Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Ann Neurol 2009; 66: 833-842.

Wang H. , Munger KL , Reindl M. , O’Reilly EJ , Levin LI , Berger T. , et al. Myelin oligodendrocyte glycoprotein antibodies and multiple sclerosis in healthy young adults. Neurology 2008; 71: 1142-1146.

von Budingen HC , Hauser SL , Ouallet JC , Tanuma N. , Menge T. and Genain CP Frontline: Epitope recognition on the myelin/oligodendrocyte glycoprotein differentially influences disease phenotype and antibody effector functions in autoimmune demyelination. Eur J Immunol 2004; 34: 2072-2083.

10.

Selter RC , Brilot F. , Grummel V. , Kraus V. , Cepok S. , Dale RC , et al. Antibody responses to EBV and native MOG in pediatric inflammatory demyelinating CNS diseases. Neurology 2010 ; 74: 1711-1715.

11.

McLaughlin KA , Chitnis T. , Newcombe J. , Franz B. , Kennedy J. , McArdel S. , et al. Age-dependent B cell auto-immunity to a myelin surface antigen in pediatric multiple sclerosis. J Immunol 2009; 183: 4067-4076.

12.

O’Connor KC , Appel H. , Bregoli L. , Call ME , Catz I. , Chan JA , et al. Antibodies from inflamed central nervous system tissue recognize myelin oligodendrocyte glycoprotein. J Immunol 2005; 175: 1974-1982.